Email Updates

You are here


To save lives, HIV treatment alone isn’t enough. Suppressing HIV is what matters.

In 2011, a landmark clinical trial showed that early initiation of anti-retroviral therapy (ART) for people who are HIV-infected cuts the risk of HIV transmission by a stunning 96 percent. The trial provided powerful new momentum to global efforts to expand treatment access — both for the health of individuals living with HIV and for the potential to prevent millions of new infections.

Getting people onto treatment, though, is only half the story. To save lives and slow the HIV epidemic, treatment needs to achieve long-term virologic suppression — meaning the level of HIV in a person’s body is essentially undetectable. In most countries, only a minority of people with HIV have their virus in check. To make viral suppression the norm, better adherence programs, viral load monitoring and other steps are urgently needed.

What We're Reading

If approved by the US Food and Drug Administration (FDA), lenacapavir could be a game changer for people living with HIV (PLWH) who have developed drug resistance on their current regimens and have limited treatment options available to them. The long-acting capsid inhibitor—administered as twice-yearly injections—could also be a convenient option for PLWH who are just starting therapy, and as an alternative to daily pills for pre-exposure prophylaxis (PrEP) as well.

September 14, 2021
The Body

People with very high pre-treatment viral loads who took dolutegravir were significantly less likely to have experienced treatment failure nine months after starting treatment compared to people taking other drugs recommended for first-line treatment, a review of more than 2000 people in the United States shows.

September 14, 2021

Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection.

August 25, 2021
Open Forum Infectious Diseases
Subscribe to RSS - Treatment